Bob Linke, MBA

Bob is a biopharma entrepreneur building and leading emerging companies raising over $75M in private and non-dilutive capital. Bob serves as CEO of Osmol Therapeutics, a Yale spinout, developing a novel treatment for chemotherapy induced peripheral neuropathy, a condition with no approved treatments that most significantly impacts breast cancer patients, the Company’s initial focus. In addition, was Executive Chairman of IonSense, Inc. until 2022 when IonSense was successfully acquired by Bruker. His early career at Baxter International, developing and commercializing pharmaceuticals and delivery systems enabled his 20+ years as a biopharma entrepreneur. He received his MBA from Harvard Business School.